135 related articles for article (PubMed ID: 21738115)
21. Pharmacokinetic, Dosimetry and Toxicity Study of ¹⁷⁷Lu-EDTMP in Patients: Phase 0/I study.
Bal C; Arora G; Kumar P; Damle N; Das T; Chakraborty S; Banerjee S; Venkatesh M; Zaknun JJ; Pillai MR
Curr Radiopharm; 2016; 9(1):71-84. PubMed ID: 25771371
[TBL] [Abstract][Full Text] [Related]
22. [Metabolic radiotherapy: what role will it have in 2001?].
George B; Douard MC; Rain JD
Cancer Radiother; 2002 May; 6(3):188-200. PubMed ID: 12116845
[TBL] [Abstract][Full Text] [Related]
23. Radiopharmaceutical therapy of bone metastases with 89SrCl2, 186Re-HEDP and 153Sm-EDTMP: a dosimetric study using Monte Carlo simulation.
Strigari L; Sciuto R; D'Andrea M; Pasqualoni R; Benassi M; Maini CL
Eur J Nucl Med Mol Imaging; 2007 Jul; 34(7):1031-8. PubMed ID: 17237963
[TBL] [Abstract][Full Text] [Related]
24. Our experience on pain palliation of bone metastasis with Sr-89 or Sm-153 in cancer patients resistant to a conventional analgesic therapy. A retrospective study.
Montesano T; Giacomobono S; Acqualagna G; Colandrea M; Di Nicola A; Travascio L; Giancamerla M; D'Apollo R; Toteda M; Ugolini F; Filesi M; Ronga G
Clin Ter; 2009; 160(3):193-9. PubMed ID: 19756320
[TBL] [Abstract][Full Text] [Related]
25. Clinical role of Sm-153 EDTMP in the treatment of painful bone metastatic disease.
Coronado M; Redondo A; Coya J; Espinosa E; Couto RM; Zamora P; Marin MD; Castelo B; Lillo ME; Frutos L; Barón MG; Curto LM
Clin Nucl Med; 2006 Oct; 31(10):605-10. PubMed ID: 16985364
[TBL] [Abstract][Full Text] [Related]
26. Samarium-153-EDTMP: pharmacokinetic, toxicity and pain response using an escalating dose schedule in treatment of metastatic bone cancer.
Farhanghi M; Holmes RA; Volkert WA; Logan KW; Singh A
J Nucl Med; 1992 Aug; 33(8):1451-8. PubMed ID: 1378887
[TBL] [Abstract][Full Text] [Related]
27. ¹⁷⁷Lu-EDTMP for treatment of bone pain in patients with disseminated skeletal metastases.
Shinto AS; Shibu D; Kamaleshwaran KK; Das T; Chakraborty S; Banerjee S; Thirumalaisamy P; Das P; Veersekar G
J Nucl Med Technol; 2014 Mar; 42(1):55-61. PubMed ID: 24503346
[TBL] [Abstract][Full Text] [Related]
28. Impact of ¹⁸F-fluoride PET-CT on implementing early treatment of painful bone metastases with Sm-153 EDTMP.
Storto G; Gallicchio R; Pellegrino T; Nardelli A; De Luca S; Capacchione D; Sirignano C; Pace L
Nucl Med Biol; 2013 May; 40(4):518-23. PubMed ID: 23522973
[TBL] [Abstract][Full Text] [Related]
29.
Alavi M; Khajeh-Rahimi F; Yousefnia H; Mohammadianpanah M; Zolghadri S; Bahrami-Samani A; Ghannadi-Maragheh M
Cancer Biother Radiopharm; 2019 Jun; 34(5):280-287. PubMed ID: 30977670
[No Abstract] [Full Text] [Related]
30. EANM procedure guidelines for treatment of refractory metastatic bone pain.
Silberstein EB; Taylor AT;
Eur J Nucl Med Mol Imaging; 2003 Mar; 30(3):BP7-11. PubMed ID: 12723557
[No Abstract] [Full Text] [Related]
31. Radionuclide therapy with bone seeking radionuclides in palliation of painful bone metastases.
Maini CL; Sciuto R; Romano L; Bergomi S
J Exp Clin Cancer Res; 2003 Dec; 22(4 Suppl):71-4. PubMed ID: 16767910
[TBL] [Abstract][Full Text] [Related]
32. Myelotoxicity of samarium Sm 153 lexidronam in patients receiving prior treatment with chemotherapy or radiotherapy.
Heron DE; Brufsky A; Beriwal S; Kurman M
Ann Oncol; 2008 Sep; 19(9):1639-43. PubMed ID: 18467311
[TBL] [Abstract][Full Text] [Related]
33. Retrospective evaluation of bone pain palliation after samarium-153-EDTMP therapy.
Sapienza MT; Ono CR; Guimarães MI; Watanabe T; Costa PA; Buchpiguel CA
Rev Hosp Clin Fac Med Sao Paulo; 2004 Dec; 59(6):321-8. PubMed ID: 15654484
[TBL] [Abstract][Full Text] [Related]
34. [Bone metastases treated with radiopharmaceuticals].
Giammarile F
Bull Cancer; 2013 Nov; 100(11):1223-7. PubMed ID: 24409472
[TBL] [Abstract][Full Text] [Related]
35. Radiopharmaceutical therapy for palliation of bone pain from osseous metastases.
Pandit-Taskar N; Batraki M; Divgi CR
J Nucl Med; 2004 Aug; 45(8):1358-65. PubMed ID: 15299062
[TBL] [Abstract][Full Text] [Related]
36. Complete scintigraphic lesion regression after single 153Sm-EDTMP therapy in prostate cancer.
Weiss K; Köck HH; Atefie K; Sinzinger H
Rev Esp Med Nucl; 2001 Jun; 20(4):311-2. PubMed ID: 11940421
[No Abstract] [Full Text] [Related]
37. Samarium-153-EDTMP in bone metastases of hormone refractory prostate carcinoma: a phase I/II trial.
Collins C; Eary JF; Donaldson G; Vernon C; Bush NE; Petersdorf S; Livingston RB; Gordon EE; Chapman CR; Appelbaum FR
J Nucl Med; 1993 Nov; 34(11):1839-44. PubMed ID: 8229221
[TBL] [Abstract][Full Text] [Related]
38. Skeletal uptake and soft-tissue retention of 186Re-HEDP and 153Sm-EDTMP in patients with metastatic bone disease.
Brenner W; Kampen WU; Kampen AM; Henze E
J Nucl Med; 2001 Feb; 42(2):230-6. PubMed ID: 11216521
[TBL] [Abstract][Full Text] [Related]
39. Pain palliative therapy in women with breast cancer osseous metastatic disease and the role of specific serum cytokines as prognostic factors.
Iakovou I; Doumas A; Badiavas K; Mpalaris V; Frangos S; Farmakis G
Cancer Biother Radiopharm; 2014 Apr; 29(3):116-23. PubMed ID: 24392878
[TBL] [Abstract][Full Text] [Related]
40. Formulation, preclinical evaluation, and preliminary clinical investigation of an in-house freeze-dried EDTMP kit suitable for the preparation of 177Lu-EDTMP.
Das T; Sarma HD; Shinto A; Kamaleshwaran KK; Banerjee S
Cancer Biother Radiopharm; 2014 Dec; 29(10):412-21. PubMed ID: 25409337
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
